MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

TG Therapeutics Company Profile (NASDAQ:TGTX)

Consensus Ratings for TG Therapeutics (NASDAQ:TGTX) (?)
Ratings Breakdown: 5 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.17)
Consensus Price Target: $25.00 (311.86% upside)

Analysts' Ratings History for TG Therapeutics (NASDAQ:TGTX)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Roth CapitalReiterated RatingBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016SunTrustInitiated CoverageBuy -> Buy$7.22 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016HC WainwrightReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Raymond JamesInitiated CoverageStrong-Buy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2015MLV & Co.Set Price TargetBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for TG Therapeutics (NASDAQ:TGTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.36)($0.28)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.34)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.32)($0.38)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.33)($0.39)$38.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q414($0.26)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q214($0.32)($0.51)$38.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/22/2014($0.28)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.19)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q313($0.22)($0.62)$0.03 million$0.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q213($0.16)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for TG Therapeutics (NASDAQ:TGTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.37)($0.37)($0.37)
Q2 20162($0.29)($0.26)($0.28)
Q3 20162($0.31)($0.27)($0.29)
Q4 20162($0.34)($0.29)($0.32)
(Data provided by Zacks Investment Research)
Dividend History for TG Therapeutics (NASDAQ:TGTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for TG Therapeutics (NASDAQ:TGTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for TG Therapeutics (NASDAQ:TGTX)
DateHeadline
06/27/16 06:39 PMShare Update and Earnings Review for TG Therapeutics, Inc. (NASDAQ:TGTX) - Press Telegraph
06/27/16 08:43 AMTG Therapeutics, Inc. (TGTX) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 05:42 PMHow Analysts Rated TG Therapeutics Inc (NASDAQ:TGTX) Last Week? - Engelwood Daily
06/26/16 05:42 PMCan TG Therapeutics, Inc. (NASDAQ:TGTX) Keep Up with Analyst Expectations? - Investor Newswire
06/23/16 09:21 AMStock Buzz: TG Therapeutics, Inc. (NASDAQ:TGTX) - iStreetWire
06/23/16 09:21 AMTG Therapeutics Inc. (TGTX) Hits New 52-week Low During June 21 Session - Equities.com
06/16/16 11:16 AMTG Therapeutics Inc. (TGTX) Hits New 52-week Low During June 14 Session - Equities.com
06/14/16 04:20 PMTG THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/12/16 09:23 AMCombination of TGR-1202 + Ibrutinib appears well-tolerated and active in relapsed/refractory CLL patients treated with the combination
06/12/16 09:23 AMTG Therapeutics (TGTX) Announces Presentation of TGR-1202 Data in CLL, NHL
06/10/16 09:51 AMTG Therapeutics (TGTX) Announces Presentation of TGR-1202 Data in CLL, NHL - StreetInsider.com
06/10/16 08:39 AMTG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Association Annual Congress - [at noodls] - June 10, 2016 NEW YORK, June 10, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced data presented during the 21 Annual Congress of the European Hematology Association (EHA) being ...
06/08/16 07:19 PMTG THERAPEUTICS INC. (NASDAQ:TGTX) Financial Condition Compared to S&P 500 - CML News
06/08/16 09:54 AMCompany Update (NASDAQ:TGTX): TG Therapeutics Inc Announces First Patient Enrolled in the Registration-Directed ... - Smarter Analyst
06/07/16 07:03 PMWeak On High Volume: TG Therapeutics (TGTX) - TheStreet.com
06/07/16 09:40 AMSunTrust Robinson Humphrey Initiates Coverage on TG Therapeutics Inc to Buy - Trade Calls
06/07/16 09:40 AMTG Therapeutics (TGTX) Enrolls First Patient in UNITY-DLBCL Phase 2b - StreetInsider.com
06/07/16 06:48 AMTG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial - [at noodls] - June 6, 2016 High response rates observed across CLL, DLBCL & indolent NHL Integrated analysis of 165 patients exposed to TGR-1202 monotherapy or the combination of TGR-1202 plus TG-1101 continues to demonstrate ...
06/06/16 10:53 AMTG Therapeutics (TGTX) to Present TGR-1202 Data in CLL, NHL at ASCO - StreetInsider.com
06/06/16 08:16 AMTG THERAPEUTICS, INC. Files SEC form 8-K, Other Events -
06/06/16 08:08 AMTG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology - [at noodls] - June 2, 2016 NEW YORK, June 02, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations at the 52 Annual Meeting of the American Society of Clinical ...
06/04/16 09:54 AMTG Therapeutics Inc (TGTX) Earns “Buy” Rating from Brean Capital - Let Me Know About This
06/04/16 09:54 AMTG Therapeutics Inc. (TGTX) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/02/16 07:17 PMTG Therapeutics Inc. (TGTX) Jumps 9.46% on June 02 - Equities.com - TG Therapeutics Inc. (TGTX) Jumps 9.46% on June 02Equities.comTG Therapeutics Inc. (TGTX) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 9.46% to $8.45, representing a gain of $0.73 per share. Some 711,299 shares traded hands on 4,911 trades, compared with an ...and more »
06/02/16 04:02 PMTG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/02/16 09:59 AMBroker Watchlist: TG Therapeutics, Inc. (TGTX) - Share Trading News - Broker Watchlist: TG Therapeutics, Inc. (TGTX)Share Trading News01/27/2014 – TG Therapeutics, Inc. was downgraded to “neutral” by analysts at Zacks. They now have a USD 5.7 price target on the stock. The share price of TG Therapeutics, Inc. (TGTX) was unchanged +0.00% during the last trading session, with a day ...and more »
06/02/16 06:35 AMTG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of the American Society of Clinical Oncology - [at noodls] - May 27, 2016 NEW YORK, May 27, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that as part of a broader agreement with Jubilant Biosys ('Jubilant'), an Indian biotechnology ...
06/01/16 07:29 PMNews Sentiment For TG Therapeutics, Inc. (NASDAQ:TGTX) - Investor Newswire - News Sentiment For TG Therapeutics, Inc. (NASDAQ:TGTX)Investor NewswireTG Therapeutics, Inc. (NASDAQ:TGTX) Average broker stands at 1 while it was 1 three months ago. The quarterly report of TG Therapeutics, Inc. (NASDAQ:TGTX) can be made public close to 2016-08-08. It is estimated by the recent update released by the ...TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Update & EstimatesStock Tick Tockall 5 news articles »
06/01/16 09:47 AMWhat's In Store For TG Therapeutics Inc. (NASDAQ: TGTX) With This Global Deal? - Scibility Media - What's In Store For TG Therapeutics Inc. (NASDAQ: TGTX) With This Global Deal?Scibility MediaTG Therapeutics Inc. (NASDAQ: TGTX) and Jubilant Biosys earlier entered into a global agreement in which TG Therapeutics will develop and later commercialize a line of Jubilant drugs for treatment of a certain type of cancer. Specifically, TG ...
05/31/16 07:10 PMTG Therapeutics, Inc. (NASDAQ:TGTX) increased 7.06%: Dawson Geophysical Company (NASDAQ:DWSN), AT&T, Inc ... - KC Register - TG Therapeutics, Inc. (NASDAQ:TGTX) increased 7.06%: Dawson Geophysical Company (NASDAQ:DWSN), AT&T, Inc ...KC RegisterTG Therapeutics, Inc. (NASDAQ:TGTX) said that, it enters into a global collaboration to develop and commercialize Novel BET inhibitors developed by Jubilant Biosys for the treatment of hematological malignancies. Under terms of agreement, TG ...and more »
05/31/16 07:10 PMTG Therapeutics Inc. (TGTX) Jumps 7.06% on May 30 - Equities.com - TG Therapeutics Inc. (TGTX) Jumps 7.06% on May 30Equities.comTG Therapeutics Inc. (TGTX) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 7.06% to $7.73, representing a gain of $0.51 per share. Some 843,587 shares traded hands on 5,139 trades, compared with an ...and more »
05/30/16 10:23 PMTG Therapeutics Incorporated (NASDAQ:TGTX) Short Interest Increased By 5.03% - HNN - TG Therapeutics Incorporated (NASDAQ:TGTX) Short Interest Increased By 5.03%HNNThe short interest to TG Therapeutics Incorporated's float is 27.08%. The stock increased 7.06% or $0.51 on May 27, hitting $7.73. About 843,587 shares traded hands or 123.68% up from the average. TG Therapeutics Inc (NASDAQ:TGTX) has declined ...and more »
05/28/16 01:22 AMTG Therapeutics Inc. (TGTX) Jumps 7.06% on May 27 - Equities.com - TG Therapeutics Inc. (TGTX) Jumps 7.06% on May 27Equities.comTG Therapeutics Inc. (TGTX) was among the biggest gainers on the Russell 2000 for Friday May 27 as the stock popped 7.06% to $7.73, representing a gain of $0.51 per share. Some 834,543 shares traded hands on 5,133 trades, compared with an average ...and more »
05/27/16 08:07 PMTG Therapeutics Inc. (TGTX) Drops 7.2% on May 26 - Equities.com - TG Therapeutics Inc. (TGTX) Drops 7.2% on May 26Equities.comTG Therapeutics Inc. (TGTX) was one of the Russell 2000's biggest losers for Thursday May 26 as the stock slid 7.2% to $7.22, a loss of $-0.56 per share. Starting at an opening price of $7.79 a share, the stock traded between $7.15 and $7.79 over the ...and more »
05/27/16 08:07 PMCompany Update (NASDAQ:TGTX): TG Therapeutics Inc Enters into a Global Collaboration to Develop and ... - Smarter Analyst - LivemintCompany Update (NASDAQ:TGTX): TG Therapeutics Inc Enters into a Global Collaboration to Develop and ...Smarter AnalystTG Therapeutics Inc (NASDAQ:TGTX), announced that as part of a broader agreement with Jubilant Biosys (“Jubilant”), an Indian biotechnology company, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics, Inc.TG Therapeutics Strikes Global Alliance To Develop Novel BET Inhibitors For Hematological Malignancies TreatmentBenzingaall 9 news articles »
05/27/16 08:00 AMTG Therapeutics Strikes Global Alliance To Develop Novel BET Inhibitors For Hematological Malignancies Treatment -
05/27/16 06:47 AMTG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors Developed by Jubilant Biosys for the Treatment of Hematological Malignancies - [at noodls] - May 27, 2016 NEW YORK, May 27, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that as part of a broader agreement with Jubilant Biosys ('Jubilant'), an Indian biotechnology ...
05/27/16 06:37 AM7:37 am TG Therapeutics confirmed Jubilant Biosy and Checkpoint Therapeutics (FBIO unit) collaboration for the treatment of hematological malignancies -
05/27/16 06:21 AMCoverage initiated on TG Therapeutics by SunTrust -
05/26/16 06:52 AMRa Capital Management LLC Increased Tg Therapeutics INC (NASDAQ:TGTX) by $13.74 Million as Shares Declined - CCH Daily News - Ra Capital Management LLC Increased Tg Therapeutics INC (NASDAQ:TGTX) by $13.74 Million as Shares DeclinedCCH Daily NewsPeter Kolchinsky increased its stake in Tg Therapeutics Inc (NASDAQ:TGTX) by 61.05% based on its latest 2016Q1 regulatory filing with the SEC. Ra Capital Management Llc bought 1.72M shares as the company's stock declined 25.33% while stock markets ...and more »
05/26/16 06:52 AMNoteworthy Buzzers: Impax Laboratories, Inc. (NASDAQ:IPXL) , TG Therapeutics, Inc. (NASDAQ:TGTX) - Street Updates - Noteworthy Buzzers: Impax Laboratories, Inc. (NASDAQ:IPXL) , TG Therapeutics, Inc. (NASDAQ:TGTX)Street UpdatesTG Therapeutics, Inc. (NASDAQ:TGTX) moved in red zone with decline of -0.03 points or -0.38% to $7.78. The company has a market worth of $420.72M.Total 427.08 thousand shares were exchanged in last trading session as opposed to average volume of ...
05/22/16 11:52 AMTG Therapeutics Inc. (TGTX) Drops 5.1% on May 19 - Equities.com - TG Therapeutics Inc. (TGTX) Drops 5.1% on May 19Equities.comTG Therapeutics Inc. (TGTX) was one of the Russell 2000's biggest losers for Thursday May 19 as the stock slid 5.1% to $7.07, a loss of $-0.38 per share. Starting at an opening price of $7.33 a share, the stock traded between $6.95 and $7.39 over the ...and more »
05/20/16 07:05 PMTG Therapeutics, Inc. (TGTX) Updated Broker Price Targets - Share Trading News - TG Therapeutics, Inc. (TGTX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of TG Therapeutics, Inc. (TGTX). The latest reports which are currently in issue on Friday 20th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
05/20/16 07:05 PMInvestor Catching Stock: TG Therapeutics Inc (TGTX) - News Oracle - StockhouseInvestor Catching Stock: TG Therapeutics Inc (TGTX)News OracleBy looking at TG Therapeutics Inc (NASDAQ:TGTX) YTD (year to date) performance, the stock shows Negative value of -40.74%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the stock is ...TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association ...Stockhouseall 3 news articles »
05/20/16 07:05 PMTG Therapeutics Inc. (TGTX) Jumps 8.63% on May 20 - Equities.com - TG Therapeutics Inc. (TGTX) Jumps 8.63% on May 20Equities.comTG Therapeutics Inc. (TGTX) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 8.63% to $7.68, representing a gain of $0.61 per share. Some 530,608 shares traded hands on 3,604 trades, compared with an average ...and more »
05/20/16 12:32 AMTG Therapeutics Inc. (TGTX) Hits New 52-week Low During May 18 Session - Equities.com - TG Therapeutics Inc. (TGTX) Hits New 52-week Low During May 18 SessionEquities.comTG Therapeutics Inc. (TGTX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $7.51, TG Therapeutics Inc. dropped to $7.17 for a new 52-week low. By the closing bell, the company's stock was at $7.45 ...and more »
05/19/16 07:09 PMShare Performance and Target Price Review for TG Therapeutics, Inc. (NASDAQ:TGTX) - Wall Street Hints and News - Share Performance and Target Price Review for TG Therapeutics, Inc. (NASDAQ:TGTX)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, TG Therapeutics, Inc. (NASDAQ ...and more »
05/19/16 12:21 AMTG Therapeutics (TGTX) Plans ASCO 2016 Presentation; Offers Details - StreetInsider.com - TG Therapeutics (TGTX) Plans ASCO 2016 Presentation; Offers DetailsStreetInsider.comTG Therapeutics, Inc. (Nasdaq: TGTX), announced that updated data has been selected for presentation at the upcoming 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in ...and more »
05/10/16 03:18 PMTG THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
05/10/16 06:07 AMQ1 2016 TG Therapeutics Inc Earnings Release - After Market Close -
About TG Therapeutics

TG Therapeutics logoTG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. As of December 31, 2014, TG had two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. As of December 31, 2014, both TG-1101 and TGR-1202 were in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop inhibitors of IRAK4 (interleukin-1 receptor-associated kinase 4), as well as an antibody research program to develop anti-PD-L1 and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies, which were in pre-clinical development as of December 31, 2014.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TGTX
  • CUSIP:
Key Metrics:
  • Previous Close: $6.07
  • 50 Day Moving Average: $7.45
  • 200 Day Moving Average: $8.90
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $328.25M
  • Current Quarter EPS Consensus Estimate: $-1.15 EPS
Additional Links:
TG Therapeutics (NASDAQ:TGTX) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha